Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dominion Energy Inc (D) vs Incyte Corporation (INCY) Price & Performance

Dominion Energy IncTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Dominion Energy Inc vs Incyte Corporation — how do they compare? Dominion Energy Inc trades at $68.02 (market cap $59.06B), while Incyte Corporation trades at $120.45 (market cap $24.65B). The key difference: Dominion Energy Inc is far larger — about 2.4× Incyte Corporation's market cap, and Dominion Energy Inc pays a 3.98% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

DINCY
Market Cap
$59.06B$24.65B
Sector
UtilitiesHealth
52-Week High
$71.67$129.93
52-Week Low
$57.08$81.61
Enterprise Value
$113.18B$20.15B
Dividend Yield
3.98%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dominion Energy Inc

Dominion Energy (D) trades at $67.39, up 0.88% today, with a bearish technical signal but strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $0.79, exceeding expectations, and maintains a stable dividend. Revenue growth is robust, rising to $16.51B in 2025, with a net income margin of 13.99%. Analyst consensus is mixed, with a $70.43 price target, but technical indicators show resistance near $68.

Outlook remains cautious due to high debt levels and bearish technicals, though fundamentals are solid with consistent profitability. Risks include regulatory pressures and capital expenditure demands. The stock offers income appeal with dividends, but near-term price action may face headwinds from technical selling pressure.

Incyte Corporation

Incyte Corporation (INCY) trades at $120.56, up 1.84% on the day, near its 52-week high of $120.70. The stock shows a bullish technical trend with strong earnings beats in Q1 and Q2 2026, including Q2 EPS of $3.09 versus $2.15 expected. Revenue growth accelerated to $5.14 billion in 2025, with a net income margin of 27.71%. Recent news highlights EU approval for Opzelura and a raised 2026 revenue outlook, fueling positive momentum.

The outlook remains favorable with analyst consensus at Buy and a $122.82 price target, though risks include reliance on key drugs like Jakafi and competitive pressures. Earnings growth and pipeline advancements support upside, but investors should monitor execution against guidance and regulatory developments.

Returns comparison

Trailing returns across standard periods

About Dominion Energy Inc

Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.

Read more on D

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY